Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The objective of this study was to evaluate the efficacy and tolerability of escitalopram versus serotonin and noradrenaline reuptake inhibitors (SNRIs) as second step treatment (defined operationally as poor response or intolerability to an antidepressant) for major depressive disorder (MDD). Results from all eligible head-to-head clinical trials of MDD (which excluded patients who earlier failed two or more antidepressants) sponsored by Lundbeck or Forest comparing escitalopram and SNRIs (venlafaxine and duloxetine) were pooled. A second step treatment subgroup was identified, defined as patients treated earlier with any antidepressant in the 6-month period before baseline. Data from three clinical trials were included in the analysis; 132 patients were identified in the second step treatment subgroup (66 in each of the escitalopram and SNRI groups). The primary efficacy analysis showed that the patients subsequently treated with escitalopram had significantly lower Montgomery Asberg Depression Rating Scale total scores after 8 weeks compared with those subsequently treated with SNRIs (difference = -6.4, P<0.0001). Escitalopram treatment was also associated with higher clinical response (73 vs. 44%, P=0.0004) and remission rates (62 vs. 41%, P=0.0083) compared with subsequent treatment with SNRIs. Escitalopram showed a better tolerability profile with lower all-cause withdrawals from study (9 vs. 23%, P<0.04) and lower withdrawals because of adverse events (2 vs. 17%, P<0.003). In conclusion, escitalopram is associated with a better efficacy and tolerability profile than SNRIs (duloxetine and venlafaxine) when used as a second step treatment in patients with MDD. These results should be confirmed in prospective randomized clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 2×
“Unauthorized reproduction of this article is prohibited. another SSRI (sertraline) or to non-SSRI agents (bupropion-SR or venlafaxine-XR) (Rush et al., 2006).”
BackgroundLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
Self-citationBerlim, M. T., & Turecki, G. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.03.009 · Cited by 249 · cited 2×
“subgroup in this study is not equivalent to that of treatment-resistant depression, although the definition of treatment-resistant depression is known to vary widely from study to study (Berlim and Turecki, 2007).”
ResultRuhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1203 · Cited by 230 · cited 8×
“Escitalopram is an SSRI that has a unique allosteric binding mechanism at the serotonin transporter protein (Chen et al., 2005).”
ResultInfluentialBielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178 · cited 2×
“Four studies were identified, two with venlafaxine (Bielski et al., 2004; Montgomery et al., 2004) and two with duloxetine (Khan et al.”
BackgroundMontgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168 · cited 2×
“Four studies were identified, two with venlafaxine (Bielski et al., 2004; Montgomery et al., 2004) and two with duloxetine (Khan et al.”
BackgroundMontgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832a8eb2 · Cited by 121
Cited by
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
“In a placebo-controlled trial of flexibly dosed escitalopram and sertraline in MDD patients, both drugs were well tolerated with similar treatment response (60 and 62%, respectively) and remission rates (46 and 46%, respectively) as compared with placebo (42% response, and 27% remission) after 8 weeks of treatment (Al…”
BackgroundInfluentialMcIntyre, R. S., Xiao, H. X., Syeda, K., Vinberg, M., Carvalho, A. F., Mansur, R. B., Maruschak, N., & Cha, D. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0263-x · Cited by 145
Zhong, H., Haddjeri, N., & Sánchez, C. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2463-5 · Cited by 105
“…serotonin and norepinephrine reuptake inhibitors (SNRIs) in patients with major depressive disorder (MDD), escitalopram is associated with a significantly lower duration of sick leave (Wade et al. 2008), as well as a better efficacy and tolerability profile (Kornstein et al. 2009; Lam et al. 2010).”
Comparative efficacy of escitalopram in the treatment of major depressive disorder
Lam, R., & Ali (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12531 · Cited by 33
Self-citation
Metadata
- Authors
- Lam, R. W., Lönn, S. L., & Despiégel, N.
- Venue
- International Clinical Psychopharmacology
- Published
- 2010-07
- Volume
- 25
- Issue
- 4
- Pages
- 199-203
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2032780198
- Cited by
- 22
- References
- 8
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. https://app.cochat.ai/papers/10.1097/yic.0b013e32833948d8
- The paper
- Lam, R. W., Lönn, S. L., & Despiégel, N. (2010). Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e32833948d8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.